HOLX Earnings Prediction
The chart below shows how HOLX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HOLX sees a -2.74% change in stock price 10 days leading up to the earnings, and a -0.91% change 10 days following the report. On the earnings day itself, the stock moves by +0.60%. This data can give you a slight idea of what to expect for the next quarter's release.
HOLX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.02B
0.86%
3.42%
Gross Margin
56.35%
3.02%
0.71%
Operating Margin
24.70%
10.37%
3.26%
Net Margin
19.67%
-19.15%
8.79%
EPS
0.87
-15.53%
14.47%
No Data Available
HOLX Earnings Analysis
Hologic Inc Corporation (HOLX.O) Earnings Conference Call
Positive
Quarterly Revenue Performance: Total revenue for the quarter was $1,022,000,000, an increase of 1% on a constant currency basis, aligning with guidance despite a $9,000,000 impact from a stronger dollar.
Earnings Per Share Growth: Non-GAAP earnings per share were $1.03, at the high end of guidance, reflecting a 5% increase and a 90 basis point improvement in non-GAAP operating margins.
Revenue Growth Overview: From 2014 to 2024, Hologic's revenue grew from approximately $2,500,000,000 to over $4,000,000,000, representing a compound annual growth rate (CAGR) of 4.8%.
Diagnostics Revenue Growth: The Diagnostics business generated revenue of $470,600,000, growing 5.29% organically, with molecular diagnostics leading the growth at 6.7% or 11% excluding COVID-related sales.
Share Repurchase Impact: In the first quarter, Hologic repurchased 6,800,000 shares for a total of $517,000,000, reducing the weighted average diluted share count to $232,000,000, an 8,000,000 share decrease compared to the prior year.
Negative
Quarterly Revenue Stagnation: Total revenue for the quarter was $1,022,000,000, reflecting only a 1% increase on a constant currency basis, indicating stagnation in growth despite previous expectations for higher performance.
Breast Health Revenue Decline: Breast health revenue declined by 2.1% or 5.8% organically, primarily driven by lower sales of capital equipment, suggesting a weakening market demand.
Revenue Guidance Reduction: The company lowered its full-year revenue guidance by $100,000,000 to a range of $4,050,000,000 to $4,100,000,000, indicating a significant downward revision in expectations due to market conditions and external factors.
Revenue Disruption Risk: A potential disruption in revenue of up to $30,000,000 was noted due to policy changes affecting HIV testing in developing countries, which could further impact financial performance.
Surgical Segment Revenue Slowdown: The surgical segment's revenue growth was only 2.5%, with expectations for high single-digit growth for the year, indicating a slowdown in momentum compared to previous periods.
HOLX FAQs
How does HOLX typically perform around its earnings report dates?
Is Hologic Inc (HOLX) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HOLX Earning Call Sentiment
Earnings call transcript: Hologic Q1 2025 sees EPS beat, revenue miss
HOLX.O
0.26%Positive
The earnings call highlights positive financial performance with increased revenue and EPS, strong guidance, and a robust share repurchase program. Despite some challenges in the breast health segment and uncertainty from the new U.S. administration, the company's growth prospects in diagnostics and surgical segments, along with strategic acquisitions, support a positive outlook. The Q&A section confirmed management's confidence in overcoming competitive and market challenges, although some responses lacked clarity. Overall, the combination of positive financial metrics and strategic initiatives suggests a likely positive stock price movement.
